Importance of steroid receptors and aromatase activity in the prognosis of ovarian cancer: High tumor progesterone receptor levels correlate with longer survival

https://doi.org/10.1016/0090-8258(89)90607-0Get rights and content

Abstract

The presence of steroid receptors (82 tumors) and aromatase activity (39 tumors) in ovarian carcinomas was correlated with patient survival. No statistically significant correlation was found between the presence or absence of estrogen receptors (ER, 56.1%), progesterone receptors (PR, 57.3%), androgen receptors (AR, 91.5%), or aromatase activity (33.3%) and survival. However, high levels of PR were associated with better survival (P < 0.05). Furthermore, there was a tendency for patients with advanced disease and PR-positive tumors to have better survival than those with advanced disease and PR-negative tumors (P = 0.13). Patients with tumors that did not contain any of the receptors and those in which ER and AR were absent, or in which PR and AR were absent, had poor survival. It is concluded that receptor status, especially of PR, may be of prognostic importance and that status of receptors and aromatase activity may become useful in selecting ovarian cancer patients for endocrine therapy.

References (44)

  • E.S. Horning

    Carcinogenic action of androgens

    Brit. J. Cancer

    (1958)
  • A.G. Jabara

    Induction of canine ovarian tumors by diethylstilbestrol and progesterone

    Aust. J. Exp. Biol.

    (1962)
  • D.J. Joly et al.

    An epidemiologic study of the relationship of reproductive experience to cancer of the ovary

    Amer. J. Epidemiol.

    (1974)
  • D.W. Cramer et al.

    Determinants of ovarian cancer risk. I. Reproductive experiences and family history

    J. Natl. Cancer Inst.

    (1983)
  • W.L. McGuire

    Steroid hormone receptors in breast cancer treatment strategy

    Recent Prog. Horm. Res.

    (1980)
  • A. Kauppila et al.

    Hormonal and cytotoxic chemotherapy for endometrial carcinoma. Steroid receptors in the selection of appropriate therapy

    Acta Obstet. Gynecol. Scand.

    (1981)
  • P. Bonomi et al.

    Primary hormonal therapy of advanced breast cancer with megestrol acetate: Predictive value of estrogen receptor and progesterone receptor levels

    Semin. Oncol.

    (1985)
  • A. Bergqvist et al.

    A study of estrogen and progesterone cytosol receptor concentration in benign and malignant ovarian tumors and a review of malignant ovarian tumors treated with medroxy-progesterone acetate

    Acta Obstet. Gynecol. Scand.

    (1981)
  • P. Vierikko et al.

    Cytosol and nuclear estrogen and progestin receptors and 17 beta-hydroxysteroid dehydrogenase activity in non-diseased tissue and in benign and malignant tumors of the human ovary

    Int. J. Cancer

    (1983)
  • G. Teufel et al.

    Östrogen- und Progesteronrezeptoren in malignen Ovarialtumoren

    Geburtsh. Frauenheilk.

    (1983)
  • M. Toppila et al.

    Steroid receptors in human ovarian malignancy. A review of four years of tissue collection

    Brit. J. Obstet. Gynaecol.

    (1986)
  • G.M. Rendina et al.

    Steroid receptors and progestenic therapy in ovarian endometrioid carcinoma

    Eur. J. Gynaecol. Oncol.

    (1982)
  • Cited by (63)

    • The role of sex hormones and steroid receptors on female reproductive cancers

      2017, Steroids
      Citation Excerpt :

      This in situ aromatization is the major source of estrogen for tumor tissues, acting as an autocrine factor for cancer cell growth and proliferation independent of circulating estrogen levels [87]. Because aromatase is expressed in 33–81% of OCs [88,89], a number of researches are evaluating the role of aromatase inhibitors (AIs) for recurrent OC treatment. The most used component of this class is letrozole, which is able to reduce estrogen production by 90% in postmenopausal women and is reported to be better than tamoxifen as a complementary therapy in breast cancer [90].

    • Dysregulation of Aromatase in Breast, Endometrial, and Ovarian Cancers: An Overview of Therapeutic Strategies

      2016, Progress in Molecular Biology and Translational Science
      Citation Excerpt :

      Aromatization of androgens to estrogens is considered the rate-limiting step in estrogen biosynthesis, and abnormal high expression of aromatase has been correlated with many gynecological malignancies, including ovarian cancers.11 Specifically, intratumoral expression of aromatase has been demonstrated to be high (33–81%) in ovarian cancers.165,166 Expression of the CYP19A1 gene encoding aromatase is essentially influenced by alternatively spliced tissue-specific promoters, i.e., 1.3, 1.6, and PII, among which PII is the key regulator of aromatase in the ovary.167

    • New insights on the role of hormonal therapy in ovarian cancer

      2013, Steroids
      Citation Excerpt :

      Aromatase inhibitors (AI) reduce estrogen production in post menopausal women by more than 90%. Aromatase expression, analyzed as either aromatase activity, mRNA expression or protein levels, has been found in 33–81% of ovarian cancers [77,78]. This wide variability in aromatase detection results from small study size (average 20–40 specimens per study) and different methods used to measure activity (activity assays and mRNA).

    View all citing articles on Scopus
    View full text